

CONMED Corporation to Ring The NASDAQ Opening Bell

July 23, 2007 7:01 AM ET

Celebrating 20 Years as a Publicly Traded Company

UTICA, N.Y., Jul 23, 2007 (BUSINESS WIRE) -- CONMED Corporation (Nasdaq: CNMD), a medical technology manufacturer and distributor of surgical devices and equipment, announced today that Joseph J. Corasanti, President and Chief Executive Officer of CONMED Corporation, will ring the ceremonial NASDAQ opening bell on Tuesday, July 24th at 9:30am ET at the NASDAQ Marketsite in Times Square, New York City.

"CONMED is pleased to celebrate our 20th anniversary on The NASDAQ Stock Market," said Mr. Corasanti. "When we were incorporated in 1970, we were solely dedicated to the manufacturing of ECG monitoring electrodes. Today, with 3,200 employees, six manufacturing facilities, and sales locations around the world, CONMED manufactures and distributes over 10,000 products in more than 100 countries. CONMED's products, many of which hold top market positions, are used by surgeons and physicians in various specialties to facilitate surgical repairs, diagnose medical problems and monitor patients' vital signs. These innovative products have helped CONMED increase revenues more than fifty fold to \$647 million in 2006 annual sales from \$12 million in 1987."

Continued innovation and commercialization of new proprietary products and processes are essential elements of CONMED's success to date and long-term growth strategy. The Company has pioneered numerous medical devices that improve patient outcomes while providing cost efficient solutions for healthcare providers. Most recently, CONMED launched the IM4000 High Definition minimally invasive Camera System, its first high definition camera system used in multi-specialty endoscopy and arthroscopy.

Mr. Corasanti added, "Since our first public offering 20 years ago, CONMED's initial public market shareholders have realized an approximate 1,200% overall return as compared to 500% for the overall NASDAQ market and 400% for the S&P 500 for the same period. CONMED's ability to access the capital markets through NASDAQ has been a critical component to our business strategy and growth over the past 20 years. We look forward to extending our continued relationship with NASDAQ into the future."

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. Headquartered in Utica, New York, the Company's 3,200 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to

forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; and/or (vii) the Company's ability to devise and execute strategies to respond to market conditions.

SOURCE: CONMED Corporation

CONMED Corporation
Robert Shallish, Chief Financial Officer, 315-624-3206
α
HD
Investors: Julie Huang/Brian Ritchie, 212-850-5600
cnmd@fd.com